Compare · EVMN vs NVO
EVMN vs NVO
Side-by-side comparison of Evommune Inc. (EVMN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVMN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 430.5x EVMN ($500.5M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for EVMN).
- NVO has more recent analyst coverage (25 ratings vs 12 for EVMN).
- Company
- Evommune Inc.
- Novo Nordisk A/S
- Price
- $13.76+0.81%
- $48.65+3.65%
- Market cap
- $500.5M
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 6
- 9
- Recent ratings
- 12
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EVMN
- Amendment: SEC Form SCHEDULE 13G/A filed by Evommune Inc.
- SEC Form SCHEDULE 13G filed by Evommune Inc.
- SEC Form 424B3 filed by Evommune Inc.
- SEC Form 10-Q filed by Evommune Inc.
- Evommune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
- Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
- SEC Form SCHEDULE 13G filed by Evommune Inc.
- Chief Financial Officer Carver Kyle bought $13,260 worth of shares (1,000 units at $13.26), increasing direct ownership by 2% to 60,335 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S